Clinical trial
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
NCT04662255 is registered in ClinicalTrials.gov with Loxo Oncology, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
- Lead sponsor
- Loxo Oncology, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- April 8, 2021
- Completion date
- June 30, 2030
- Enrollment
- 500 (estimated)
- Sites
- 189
Conditions
As the registry lists them; a condition with its own page is linked.